June 25, 2020
According to the research report titled ‘3D Printed Drugs Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Dosage Forms; Technology, available with Market Study Report, global 3D printed drugs market was worth USD 28.52 million in the year 2019 and is expected to grow with a CAGR of 9.1% during the forecast period, subsequently accounting for USD 57.03 million by the year 2027.
For the uninitiated, 3D printed drugs are medications developed using 3D printing tools in order to offer effective and safe personalized drugs to patients. These drugs help in removing the need for sallow high-dose medicines since they comprise of unitary porous structures and easily disperse in the mouth after consumption.
Rising adoption of personalized medications along with technological advancements in 3D printing are projected to enhance the sales of 3D printed drugs in the ensuing years t. The application of 3D printing technology to develop personalized drug therapies also helps in improving patient care. High occurrence of dysphagia is also aiding the market expansion.
Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/2623845/
Shifting focus of pharmaceutical research organizations towards the development of customized treatment methods in order to make medications more effective and safer are further stimulating the industry outlook. However, rising concerns regarding illegal utilization of 3D printing tools for producing drugs may act as a restraining factor to the overall market growth.
As per dosage forms, the 3D printed drugs market is split into solutions, nanoparticles, multi drug implant, capsules, tablets, and others. The report states that the tablet segment accounted for a substantial share of the overall market in 2019 and is predicted to expand significantly during the forecast period.
In terms of technology, the industry is divided into SEE (semi solid extrusion), SLA (stereolithography), powder bed printing, fused deposition modeling, thermal inkjet printing, zip dose, direct write and inkjet printing. The zip dose segment is expected to showcase healthy growth in the forthcoming years, claim industry analysts.
MSD UK, Tvasta Group, Merck KGaA, FabRx Ltd., AstraZeneca, Aprecia Pharmaceuticals LLC and GlaxoSmithKline Plc. are the major companies formulating the competitive arena of global 3D printed drugs market.